Investigating The Molecular Profile Of Standard-risk Acute Myeloid Leukaemia (AML) In The NCRI AML19 Trial.

Project: Research

Project Details

StatusActive
Effective start/end date1/11/202430/04/2025

Collaborative partners

Funding

  • Jazz Pharmaceuticals, plc: £187,264.00